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Background: Carcinoid tumors are rare tumors that, despite advances in medical research, have 
remained enigmatic. Carcinoid tumors can be categorized using gross pathological, histological, 
and biochemical profiles. While of some utility, this classification method fails to enable accurate 
determination of malignant potential. Incorporation of molecular analysis of carcinoids will create 
a paradigm shift in classification. To this end, high throughput technologies such as Quantitative 
RT PCR, Tissue Microarray, and cDNA Microarray will facilitate such changes.  
In our investigations, cDNA microarray analysis identified Metastasis-associated protein-1 
(MTA1), Histone Deacetylase 2 (HDAC2), and aberrant transcriptional regulation as factors 
involved in the molecular pathogenesis of SICs. HDAC2 mediates histone deacetylation, 
resulting in chromatin remodeling and transcriptional repression while MTA1, found in complex 
with HDAC2, is not only a mediator of transcriptional repression, but also of cell growth and 
motility. These proteins, as mediators of epigenetic processes, are markers of malignancy in 
gastric, breast, colorectal, and hematological malignancies. HER2 has been implicated in MTA1 
upregulation in the breast cancer model. Analysis of HDAC2 and MTA1 expression and their 
roles in SIC malignancy could potentially alter SIC classification and lead to the investigation of 
anti-epigenetic cancer strategies such as HDAC inhibitors. 
Hypothesis: MTA1 and HDAC2 (MTA1/HDAC2 complex), involved in transcriptional 
regulation are both markers of SIC malignancy and function in SIC pathogenesis. HER2 mediates 
MTA1 upregulation in SICs, as in breast tumors. HER2, ER, and CpG island methylation may be 
involved in SIC tumorigenesis by regulating MTA1 expression. 
Methods: The gene expression profile of eight (8) GI carcinoid samples was analyzed using 
Afffymetrix ™ Gene Chip ® technology. Transcript expression of HDAC2, MTA1, HER2, ER2, 
and Trefoil Factor 1 (TFF1) was examined in normal mucosa and SIC samples using Quantitative 
RT-PCR. Protein expression of HDAC2, MTA1, HER2, ER2, and TFF1 was measured on a 
carcinoid tissue microarray containing 55 SIC tumor samples with matched normal mucosa. 
HDAC activity was quantified directly through an enzymatic assay and Trichostatin A (TSA) 
inhibition and indirectly by analysis of histone acetylation on TMA. MTA1 upregulation in SICs 
was explored through analysis of HER2 gene and protein expression patterns and of the MTA1 
promoter region. 
Results: Affymetrix GeneChip and Ingenuity Pathway analysis identified aberrant transcriptional 
repression mediated by MTA1 and HDAC2 as a principal pathway in SICs. Q-RT-PCR: MTA1: 
nml-1.68±0.16, primary- 3.58±1.5*, mets-5.96±2.4#; HDAC2: nml-0.07±0.02, primary-2.0±0.8&, mets-
4.1±0.6&; HER2: nml-2.28±0.51, primary-1.02±0.23*, mets-0.8±0.39#; ERα: nml-0.49±0.19, primary- 
5.71±3.1#, mets-3.01±1.4#; TFF1: nml-0.86±0.21, primary- 0.005±0.002*, mets-0.0059±0.0018*. TMA 
analysis: MTA1: nml-3±1 local-75±12#, disseminated-78±1#; HDAC2: nml-524± 81. local-712±101#, 
disseminated-762±105#; HER2: nml- 10±1, local-9±1NS, disseminated-6±0.5NS; ERα: nml- 11±0.5, local-
10.1±1NS, disseminated-12±0.5NS; TFF1: nml- 98, local-83±5NS, disseminated-75±4NS.HDAC activity in 
SICs: nml- 0.08, nml with TSA- 0.04, SIC- 0.32, SIC with TSA- 0.081. Indirect HDAC activity 
assessment through TMA: nml- 757±116, local- 502±121#, disseminated- 523±112#.Ratio of 
acetylated to unacetylated H2B: nml- 1.74, SIC-1.43. (*p=0.05, #p<0.05, NS=not significant) 
Analysis of the MTA1 promoter region revealed c-Myc, c-Fos/c-Jun, c-Myc, SP1 responsive 
elements as well as CpG islands. Attempts to amplify the MTA1 promoter region were 
unsuccessful.  
Conclusion: HDAC2 and MTA1 are functional markers of SIC malignancy. Both transcript and 
protein expression increased as tissue progressed from normal SI mucosa to primary SIC to 
metastatic SIC tissue. Involved in epigenetic processes, these proteins and their respective 
pathways may be potential therapeutic targets of HDAC inhibitors. Low HER2 expression and a 
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lack of correlation with MTA1 expression suggests other mechanisms of MTA1 upregulation in 
SIC tissue. These may include c-Myc, c-Fos/c-Jun, c-Myb, SP1, and CpG island (de)methylation. 
Further investigations will provide more information regarding modes of MTA1 upregulation in 
SIC. Overall, epigenetic modulation via the MTA1/HDAC2 complex may be of importance in 
SIC tumorgenesis and molecular analysis may be a means of enhancing SIC classification with a 
view to facilitating improved diagnosis, prognostication, and therapeutic strategy. 
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Carcinoid tumors are rare tumor entities that, despite much advancement in 
medical research, have remained enigmatic. Previously considered to be benign relative 
to adenocarcinomas, many cases have shown, to the contrary, that carcinoid tumors have 
the potential to behave rather aggressively, resulting in a complicated disease course. 
Comprising 67% of all diagnosed carcinoid tumors(1), gastrointestinal (GI) carcinoids 
occur most frequently in the small intestine, the rectum, and the stomach. An examination 
of their 5-year survival rate- 60.5%, 88.3%, and 63.0%, respectively(1)- suggests points 
of divergence in their molecular biology and, concomitantly, in their disease course. With 
their very own unique biological and clinical characteristics, GI carcinoid tumors deserve 
closer scrutiny and further elucidation of their nature. 
Past methods of carcinoid tumor classification have incorporated gross 
pathological, histological, embryological, and biochemical criteria. While of some utility, 
these methods fail to provide a means with which to determine malignant potential which 
could facilitate prognostication. In addition, the exploration of the molecular biology of 
carcinoid tumors may lead to the targeted design of therapeutic approaches.  
This thesis explores molecular methods of small intestinal carcinoid (SIC) 
classification while elucidating potential molecular pathways involved in their 
tumorigenesis. In our investigations, we have employed cDNA Microarray, Pathway 
Analysis, Q-RT-PCR, Tissue Microarray, and Enzymatic Assays in order to further 
define the molecular nature of SICs. 
Our preliminary gene expression profile data [FIGURE 2] has led to a focus on 
histone deacetylase 2 (HDAC2) and metastases associated protein-1 (MTA1). Found in 
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complex, these two proteins are major components of epigenetic processes. Epigenetics is 
a field that involves the study of changes in gene function that are mitotically and/or 
meiotically heritable. These changes do not involve alterations in nuclear DNA sequence 
(2, 3). The major modes of epigenetic modulation include methylation and histone 
(de)acetylation. HDAC2 is a mediator of histone deacetylation through a hydrolytic 
process that induces chromatin remodeling. Such alterations result in a transcriptionally 
inactive DNA conformation (4). Increases in HDAC2 expression levels have been noted 
in gastric(5) and colorectal carcinomas(6). MTA1, found in complex with HDAC2 (7), is 
involved not only in transcriptional repression (8), but has been implicated in cellular 
growth (9) and motility (10). Increased levels of MTA1 have been found in breast (11), 
hepatocellular (12), esophageal (13), gastric, and colorectal (14) carcinoma patients with 
evidence of metastasis or aggressive disease course. 
We hypothesize that aberrant transcriptional regulation, mediated by the 
MTA1/HDAC2 complex, may be central to SIC tumorigenesis and the development of 
metastatic qualities. Thusly, MTA1 and HDAC2 have functional roles in SIC 
development and may aid in the classification of SIC subtypes, thus facilitating improved 
diagnosis, prognostication and therapeutic strategy. 
 
2. A Brief Overview of Gastrointestinal Carcinoids 
2a. Early History 
Prior to Siegfried Oberndorfer’s 1907 introduction of the term karzinoid (15) 
(carcinoma-like), there were a number of early reports of these unique tumor entities. In 
1867, T. Langhans wrote of a firm, mushroom-shaped submucosal tumor that was 
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histologically described as poorly differentiated glandular tissue arranged in ‘nests’ with 
a rich, thick fibrous stroma (16). An 1888 autopsy by O. Lubarsch revealed multiple 
similar ileal tumors, but he hesitated to call them true carcinomas (17). In 1890, W.B. 
Ransom also reported ileal tumors with similarly described unique characteristics, but in 
addition, emphasized the associated symptoms which included diarrhea and wheezing, 
thus the first documentation of carcinoid syndrome (18). In 1907, Oberndorfer described 
the small intestinal tumors as follows: “mostly small and multiple, tend to be surrounded 
by undifferentiated tissues, have the potential to become invasive, do not metastasize, and 
grow extremely slowly and are, therefore, of a harmless nature (15).” This benign 
assessment of these tumors was later refined when further analysis led Oberndorfer to 
note the malignant potential of these karzinoid tumors (19).  
2b. The Enterochromaffin Cell: Cell of GI Carcinoid Origin 
Distinguished by its deep yellow stain pattern upon exposure to bichromate 
solutions, the enterochromaffin cell (EC), first described by R.P. Heidenhain (20) in 
1896, is found in the crypts of Lieberkuhn of the GI mucosa (N. Kulchitsky 1897 (21)). 
The actual term ‘enterochromaffin’ was introduced by M.C. Ciacco (22) in 1906 in order 
to categorize the cells with regards to staining properties and anatomical location.  
One of the earliest links between carcinoid tumors and their EC cell origin was 
presented by the studies of A. Gosset and P. Masson (1914) (23). In 1948, A.B. Dawson 
had developed a technique by which EC and enterochromaffin-like (ECL) cells of the 
gastrointestinal tract could be stained using silver nitrate (24). Many decades later, Solcia 
et al. (1969) perfected the method to differentiate EC cells with various chemical staining 
techniques (including chromaffin, argentaffin, and diazonium) which were noted to react 
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specifically with 5-hydroxytryptophan (5-HTP), an EC cell-specific product (25). Further 
demonstrating the EC cell-carcinoid link was the work of F. Lembeck (1953) which 
biochemically confirmed the presence of 5-Hydroxytryptamine (5-HT) in an ileal 
carcinoid tumor (26). [FIGURE 1] 
 
Figure 1. Timeline of Major Events in Carcinoid History 
 
2c. Classification  
In an attempt to define carcinoid tumors, a number of classifications have been 
proposed. In 1963, Williams and Sandler classified these tumors based on their putative 
embryological origin (foregut, midgut, or hindgut) (27). Despite the simplicity of this 
system, it became apparent that carcinoid tumors differed greatly as far as morphology, 
function, and biology—rendering embryological classification to be of little utility. This 
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system, however, remained the general convention despite the fact that it proved too 
imprecise and failed to convey the diverse spectrum of neoplasms with widely different 
secreting products that originate from different neuroendocrine cell types (28).  
In 1971, J. Soga and Y. Yakuwa introduced a histological approach to the 
classification of carcinoids, describing the tumors according to their dominant growth 
pattern: insular, trabecular, glandular, mixed, or undifferentiated. This system combined 
histological findings, silver staining patterns, electron microscopy findings of specific 
secretory granules, and routine clinical investigations such as biochemistry (5-
hydroxytrytophan, 5-hydroxyindole acetic acid or histamine) and clinical history with 
physical findings (29). This combination served to morphologically classify tumors while 
incorporating clinical parameters.  
A. Pearse recognized an important cytochemical commonality between the 
endocrine cells of the gut: the uptake of 5-HTP and its decarboxylation to 5-HT 
(serotonin) (30). By 1968, these peptide hormone-producing cells, all of which derived 
from the neural crest, were collectively called APUD (Amine Precursor Uptake and 
Decarboxylation) cells (31), While Pearse and others initially suggested that APUD cells 
were derived from neural crest cells, it is now generally recognized that 
gastroenteropancreatic APUD cells probably arise from the endoderm (32). 
Most recently, Kloppel et al. (33) presented an updated World Health 
Organization system for the classification of neuroendocrine tumors of the 
gastroenteropancreatic system (2004) in an attempt to improve terminology, avoid 
variances in definition, and provide a uniform basis for assessment. In brief, three main 
categories were created: well-differentiated neuroendocrine tumors (NETs), well-
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differentiated neuroendocrine carcinomas (NECs), and poorly differentiated NECs. The 
term ‘carcinoid’ was retained to refer to gastrointestinal NETs that are well-differentiated 
neuroendocrine tumors. Overall, the goal was to provide a prognostically relevant 
classification system that assessed tumors according to size, proliferative activity, 
angioinvasion, organ invasion, metastases, hormonal activity, and clinical syndromes.  
2d. Epidemiology 
Gastrointestinal carcinoids fall under a broader category of tumors- 
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). This classification 
includes pancreatic tumors such as insulinomas and gastrinomas. Uniting these tumor 
types is their derivation from cells of neuroendocrine origin and the secretion of 
chromogranin A (34) (CgA), synapotophysin (35), and neuron-specific enolase (36) 
(NSE). Specifically examining carcinoids, multiple epidemiological analyses have been 
undertaken to further our understanding of carcinoid incidence, distribution, and survival. 
Despite the rarity of these tumors, multiple epidemiological analyses have been published 
using either post-mortem evaluation (37) or, more recently, population registries (1, 38, 
39). 
In 1975, Godwin (38) provided a fundamental contribution in his evaluation of 
carcinoid tumor incidence, distribution, and survival in the United States. The survey 
analyzed 2,837 carcinoid cases registered between 1950 and 1971. This body of work 
examined a heterogeneous population, noting higher age-adjusted incidence rates for 
black males, with the exception of bronchopulmonary carcinoids, and 5-year survival 
rates as high as 99% in the appendix and as low as 33% in the sigmoid colon.  
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Most recently, Modlin et al. (1) (2003) provided a 5-decade analysis (1950-1999) 
of carcinoid tumors (n=13,715). Overall, carcinoid tumor incidence appears to have 
increased with gastrointestinal (GI) carcinoids representing the largest group (67.5%). GI 
carcinoids are found most frequently in the small intestinal (41.8%), rectum (27.4%), and 
stomach (8.7%). Nonlocalized disease was most frequently found in cecal (81.5-83.2%) 
and pancreatic (71.9-81.3%) cases. While the overall 5-year survival rate for carcinoid 
neoplasms was 67.2%, patients with rectal, bronchopulmonary, and appendiceal 
carcinoids had the highest 5-year survival rates (88.3%, 73.5%, and 71.0%). These 
numbers refute the popular notion that these tumors are relatively homogeneous and 
benign in both nature and clinical course. Considering race, blacks and Asians had a 
disproportionate representation in rectal carcinoids, suggesting the potential role of 
genetic predisposition for this tumor subtype. The overall apparent increase in carcinoid 
incidence over the 50-year survey may be attributed to increased knowledge, the 
evolution of diagnostic and imaging modalities, and the increase in endoscopic 
investigations. 
2e. Clinical Presentation and Complications 
In 1890, W.B. Ransom provided the first account of carcinoid syndrome in a 
patient with ileal tumors and hepatic metastases (18). The symptomatology associated 
with carcinoid disease may be due to tumor mass effects, carcinoid-associated fibrosis, 
and syndrome symptoms such as cutaneous flushing, diarrhea, and bronchospasm caused 
by biologically active products secreted by the tumor into the bloodstream (40). 
Unfortunately, only 10% of patients may present with carcinoid syndrome (37), thus 
presenting a diagnostic challenge for clinicians. This condition is often mistaken for 
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menopause or Irritable Bowel Syndrome, thus delaying diagnosis and appropriate 
treatment (40). 
Much of carcinoid symptomatology is attributed to the release of serotonin (5-
HT) from the carcinoid tumor cells. Serotonin was first isolated and described by M. 
Rapport in 1948 (41). This biologically active substance was extracted from EC cells in 
1952 (42). The following year, F. Lembeck confirmed the presence of 5-HT in an ileal 
carcinoid (26). These findings would later lead to a biochemical means of carcinoid 
diagnosis through the examination of patient serum. 
A major complication of carcinoid disease is the development of fibrosis. In 1931, 
A.J. Scholte first reported the cardiac manifestations of carcinoid disease in a patient with 
an ileal tumor, symptoms of congestive heart failure, and thickened tricuspid valves and 
right atrial endocardium on autopsy (43). Thirty years later, C. Moertel drew the link 
between carcinoids and fibrosis (44).  
Fibrotic changes are not only found in the heart. They may also occur in the 
bronchopulmonary system (45), the mesentery, and the retroperitoneum, causing 
complications such as bowel obstruction (46) and hydronephrosis secondary to stenosis 
of the ureters (47). The exact mechanism of this fibroblastic process in the mesentery 
does not appear to involve serotonin as its levels do not seem to correlate with the 
development of fibrotic disease (48). In addition, serotonin alone does not stimulate 
fibroblast growth according to in vitro studies (49). On the contrary, increased 5- 
hydroxyindoleacetic acid (5-HIAA), a product of serotonin degradation, correlates with 
increased incidence of carcinoid cardiac involvement (50, 51).  
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The pathogenesis of fibrotic processes in carcinoid disease involves Transforming 
Growth Factor- Beta (TGF-β), a potent stimulator of fibroblast proliferation (52), and 
Connective Tissue Growth Factor (CTGF), a downstream mediator (53). TGF-β has been 
found in fibrotic cardiac carcinoid lesions (54) while CTGF has been found in excessive 
amounts in the serum of carcinoid patients with fibrotic disease (55). These growth 
factors may work in concert in the presentation of fibrotic complications. It is, therefore, 
judicious to direct future efforts towards therapeutic mediators of these growth factors, 
thus potentially halting fibrotic progression in carcinoid disease. 
2f. Biochemical Diagnosis 
Critical to the diagnosis of carcinoid disease is biochemical analysis. In 1954, I.H. 
Page demonstrated the utility of serotonin as a plasma marker for carcinoid disease. He 
also observed elevated urinary excretion of the main serotonin metabolite, 5-HIAA, in a 
patient with carcinoid syndrome (56). Today, the measurement of urinary 5-HIAA over a 
24-hour period is still utilized in order to provide clinicians with an estimation of tumor 
activity. This however, is not as sensitive as the measurement of serum Chromogranin A 
(CgA). CgA is a neuroendocrine tumor marker with elevated levels in carcinoids, 
pancreatic endocrine tumors, and prostatic carcinoma (57). Its measurement provides 
information regarding tumor burden (58). Both CgA and 5-HIAA, while diagnostic, are 
also valuable in following the patient’s clinical course. High levels of urinary 5-HIAA, 
for instance, are associated with increased risk of cardiac carcinoid disease (59) as well as 
perioperative complications (60). Such information may serve as a guide to clinical 
decisions.  
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2g. Diagnostic Imaging 
Multiple imaging modalities exist to aid in localization of carcinoid disease. 
Luminal examination is facilitated by barium studies (61), enteroclysis (62), endoscopy 
(63), and capsule endoscopy (64). These modalities, while useful, are not the definitive 
diagnostic studies of choice. 
CT and MRI will facilitate visualization of mass lesions, calcifications, and 
evidence of fibrosis (radiating strands and spiculation) and have detection and sensitivity 
rates of 80% (65). Neuroendocrine-specific modes such as Somatostatin Receptor 
(SSTR) scintigraphy (SRS) with 111Indium labeled octreoscan (66) and 11C-5HTP PET 
scan (67), can detect not only primary tumors, but also areas of metastasis and active 
carcinoid activity. A recent study has shown that 11C-5HTP PET is able to detect more 
lesions when compared with CT and SRS (68). These modes of imaging incorporate our 
current understanding of carcinoid biology. 
2h. Therapeutic Approaches 
2h.i. Medical Interventions 
Early attempts to relieve symptoms associated with carcinoid syndrome have 
included treatment with methysergide (69), chlorpromazine (70), p-chlorophenylalanine 
(71), and cyproheptadine hydrochloride (72). All of these drugs have proven effective in 
decreasing diarrhea, but had little efficacy in combating flushing.  
Prior to the current understanding of somatostatin receptors and their importance 
in carcinoid disease, chemotherapy became a therapeutic strategy in the eradication of 
carcinoid tumor disease and the relief of carcinoid-associated symptoms. 
Chemotherapeutics have included monotherapies such as Actinomycin D (73), 5-
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Fluorouracil (74), Dacarbazine (73), Streptozotocin (75), and cis- Platinum (76) along 
with combination chemotherapy such as cyclophosphamide with methotrexate (77) and 
5-fluorouracil with streptozotocin (77). Unfortunately, none of these strategies were 
successful and results were often inconsistent. The lack of success with 
chemotherapeutics is likely due to the slow, indolent course of carcinoid tumor growth. 
Given their mechanisms of action, these drugs are most effective in rapidly proliferating 
tumor types. Overall, chemotherapeutics had an efficacy rate ranging from 7 to 40% (78). 
A more sophisticated knowledge of somatostatin, its receptors, and their 
association with carcinoid tumors created a complete shift in the clinician’s approach to 
carcinoid syndrome. Somatostatin was first isolated by P. Brazeau (79) in 1973. This 
peptide was thought to have an effect on growth hormone release through inhibition. 
Later studies would reveal this hormone’s multi-functional capacity, affecting motor and 
cognitive function, gastrointestinal motility, absorption in the gut, and even cell growth 
and proliferation (80-82). Unfortunately, somatostatin’s potential in the alleviation of 
carcinoid syndrome symptomatology is hampered by its extremely short half-life (2-4 
minutes) (83). This greatly affects the utility of this hormone as a therapeutic approach to 
carcinoid disease. In 1982, W. Bauer et al. (84) reported the creation of SMS-201-995 
(octreotide), a potent somatostatin analogue with a half-life of 1.5 to 2 hours. Three years 
later, it was used in the treatment of carcinoid disease (85). The same year (1985), 
octreotide was introduced in the operating room and utilized in the successful 
intervention of intraoperative carcinoid crisis (86). In 2002, SOM230 was developed as a 
somatostatin analogue with receptor affinity for all somatostatin receptor sub-types (87).  
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The introduction of long-acting somatostatin analogues has created a new 
direction in carcinoid syndrome symptom control. Today, somatostatin analogues may be 
administered subcutaneously every 6 to 12 hours (Sandostatin; Novartis, East Hanover, 
NJ) or in a depot form (Sandostatin LAR; Novartis, East Hanover, NJ) every 2 weeks. 
Both regimens effectively control carcinoid syndrome symptomatology in 70-80% of 
patients (88, 89). Associated side effects include gallbladder stones, cardiac arrhythmias, 
and endocrine abnormalities such as hypothyroidism and hypo/hyperglycemia (90). 
Given the risk of gallstone formation and cholelithiasis, it is judicious for carcinoid 
patients to undergo prophylactic cholecystectomy (91). 
In addition to a somatostatin analogue treatment regimen, human leukocyte 
interferon (HLI), interferon-alpha, and interferon-beta appear to be of utility as 
demonstrated by the reduction of biochemical markers and by objective tumor shrinkage 
(92-95). A serious adverse effect profile which includes myelosuppression may impede 
its wide-spread use (90, 96).  
2h.i.a. Radio-labeled Somatostatin Analogues  
Cells expressing somatostatin receptors have the ability to internalize somatostatin and its 
analogues (97). Taking advantage of this phenomenon, scientists and clinicians have 
investigated the use of radiotherapy in tumors with strong express of somatostatin 
receptors. 111Indium and 90Yytrium-labeled somatostatin analogues have been utilized 
with variable responses. 111Indium radionuclide therapies elicited response rates between 
13 and 20% (98-101) while [90Yytrium-DOTA0Tyr3] octreotide induced partial 
remissions in 10 and 30% of subjects (102, 103). [177Lutetium- DOTA0Tyr3] octreotate 
had more promising results with complete or partial responses in 30% of patients and 
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tumor response in 48% (104, 105). Future developments in the area of radio-labeled 
somatostatin analogue therapeutics may lead to effective GI carcinoid eradication. 
2h.ii. Surgical Interventions 
The goal of surgical intervention is the resection of the primary tumor and 
reduction of tumor bulk in areas of metastases, particularly in the liver. These 
interventions serve to alleviate mechanical complications such as bowel obstruction (106) 
and, in many cases, relieve carcinoid-associated symptomatology (107). In surgical cases 
with residual tumor, SST analogues may be given to given to effectively control the 
symptoms of carcinoid syndrome (90). 
Not all cases of gastrointestinal carcinoid will require laparotomy. Some, such as 
gastric (subtypes I and II) and rectal carcinoids, may be amenable to endoscopic excision 
approaches (108, 109). In the case of hepatic metastases, multiple options are available. 
These include hepatic resection (110), radiofrequency ablation (111), and embolization 
with or without cytotoxics or isotopic microspheres (111, 112). In rare cases, a hepatic 
transplant (five-year survival rate of 69%) may be pursued (113, 114). 
Multiple options exist for the gastrointestinal carcinoid patient. The future 
direction of therapeutic approaches will be greatly aided by improvements in diagnosis 
and knowledge of carcinoid tumor biology. Such developments will guide clinical 
decisions and improve patient outcome. 
 
3. Challenges in Advancement of Gastrointestinal Carcinoid Knowledge 
While much has been gained in the century since Oberndorfer’s pivotal 
contribution, we have yet to harness the ability to accurately characterize carcinoid 
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tumors with regard to their malignant potential and clinical course. This challenge may be 
surmounted by novel molecular analytic techniques. Until then, biological basis of 
gastrointestinal carcinoids remains enigmatic.  
3a. The Current Status of GI Carcinoid Classification 
The updated World Health Organization system for the classification of 
neuroendocrine tumors (NETs) of the Gastroentero-Pancreatic (GEP) system (2004), 
presented by Kloppel et al.(33), serves to redefine nomenclature utilized to distinguish 
between carcinoids, pancreatic endocrine tumors such as insulinomas, and other tumors 
of the GEP system of neuroendocrine origin. The categories include well-differentiated 
neuroendocrine tumors (NETs), well-differentiated neuroendocrine carcinomas (NECs), 
and poorly differentiated NECs.  Carcinoids are categorized as well-differentiated NETs. 
While this system may serve to provide a basis of classification with a view to 
prognostication, it still depends on traditional methods used by previous systems, namely 
histology, clinical presentation, and biological activity. Despite the advances in molecular 
biology and genetic analysis, we have yet to incorporate these tools into classification 
methodologies. 
3b. Molecular Biology and the Future of GI Carcinoid Classifiction 
The future of GI carcinoid classification will rely more and more on molecular 
genetic analysis. Numerous investigations have uncovered a number of molecular 
alterations in GI carcinoids. 
An interrogation of the molecular basis of carcinoid tumorigenesis through 
Comparative Genomic Hybridization (CGH) and Microsatellite Analysis methods 
highlights their heterogeneous nature and divergent developmental pathways. Differences 
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include chromosomal losses or gains found strictly in the foregut versus midgut 
carcinoids (115). Even among subtypes of gastric carcinoids (type I associated with 
atrophic gastritis, type II associated with Zollinger-Ellison syndrome, and type III, 
sporadic and the most malignant), genetic differences were observed in the loss of 
heterozygosity in the X chromosome. Loss of heterozygosity (LOH) of the X 
chromosome was found in 50% of the type III gastric carcinoids but in none of the type I 
gastric carcinoid tumors. Tumors that had LOH were associated with the presence of 
metastasis (116). Regarding midgut carcinoids, CGH analysis showed distinct losses in 
16q and gains in chromosome 4, distinguishing primary from metastatic carcinoid issue 
(117). 
It is apparent that the delineation of the molecular basis of carcinoid tumor 
development and evolution will provide a reliable means to characterize them, facilitate 
diagnosis, rationalize therapy, and establish prognostic protocols. The tools in our 
armamentarium include quantitative RT-PCR (118), automated tissue microarray analysis 
(119), CpG Island Methylation analysis (120), and cDNA microarray (121) coupled with 
pathway analysis, to name a few. The incorporation of these molecular techniques in 
carcinoid investigation will provide the impetus for a paradigm shift, thus enhancing 
current classification strategies. 
The utility of cDNA microarray analysis and molecular signatures has been 
demonstrated in colonic (122, 123), breast (124, 125), and bladder (126) carcinomas. The 
results of these studies could potentially alter treatment protocols for cancer patients. In 
2004, Y. Wang et al.(123) utilized Affymetrix™ cDNA microarray technology to find 
prognostic markers for tumor relapse in patients with Dukes’ B Colon Cancer. Colonic 
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carcinomas under this classification extend into or through muscular layer and have no 
nodal involvement. Unfortunately, 25 to 30% of patients develop recurrence and die 
(127) which created a controversy over appropriate administration of adjuvant 
chemotherapy (128). Wang et al. identified a 23-gene signature that predicts recurrence 
with an overall performance accuracy of 78%. This data may aid in appropriate 
therapeutic decisions according to genetic profile as it revealed patients at a high risk of 
relapse (13-fold) who would be appropriate candidates for adjuvant therapy similar to 
Dukes C patients (123). cDNA microarray technology and gene expression profiling have 
the potential to change therapeutic rationale, thus improving patient outcome. 
The work of Wang et al. is demonstrative of the potential power of the 
incorporation of molecular analysis in diagnostic, therapeutic, and prognostic strategies. 
Within the realm of gastrointestinal carcinoids, little molecular information has been 
uncovered to date (reviewed in Zikusoka et al., 2005 (129)). With the advent of high 
throughput technologies such as cDNA microarrays, tissue microarrays, and quantitative 
real time PCR, it may be possible to further our current understanding of the molecular 
basis of GI carcinoid tumorigenesis. 
 
4. Molecular Focus: Epigenetics and Small Intestinal Carcinoids 
The goal of this thesis is to explore molecular methods of small intestinal 
carcinoid (SIC) classification while elucidating potential molecular pathways involved in 
their development and acquisition of malignant traits. A preliminary investigation of the 
gene expression profile of SIC through Affymetrix™ GeneChip® analysis has led to a 
focus on histone deacetylase 2 (HDAC2) and metastasis associated protein-1 (MTA1) 
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[FIGURE 2]. These two proteins are components of epigenetic processes: HDAC2 as a 
mediator of histone deacetylation and chromatin remodeling (4), and MTA1, found in 
complex with HDAC2,(7) not only as a mediator of transcriptional repression (8) but of 
cellular growth (9) and motility (10). 
4a. Epigenetics Overview  
Epigenetics is defined as the study of changes in gene function that are mitotically 
and/or meiotically heritable and do not involve a change in nuclear DNA sequence (2, 3). 
Methylation and histone acetylation/deacetylation are modes of epigenetic modulation. 
Before a discussion of epigenetics and its potential role in tumorigenesis, a brief review 
of DNA packaging is presented. 
Genetic material is packaged into chromatin (130, 131). This chromatin is 
composed of nucleosomes and DNA. In each nucleosome, roughly two superhelical turns 
of DNA (approximately 146 base pairs) wrap around an octamer of core histone proteins 
formed by four histone partners: H3-H4 tetramer and 2 H2A-H2B dimers bound by H1, a 
linker histone (132). Histones are small basic proteins with a positively charged N-
terminus that protrude from the nucleosome. They are involved in the determination of 
the level of DNA condensation. 
4a.i. Histone (De)Acetylation 
The addition of acetyl groups to the N-terminal tails of the histones is a means of 
influencing the level of chromatin condensation, and thus the transcriptional activity, of a 
genetic region. This process is catalyzed by histone acetyltransferases (HATs) and the 
hydrolysis of the acetylated histone tails is facilitated by histone deacetylases (HDACs) 
(133). The acetylation of histone proteins neutralizes the positive charge, resulting in the 
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disruption of higher order structures in chromatin (134), thus enhancing the access of 
transcription factors and RNA polymerases to promoter regions of DNA. Deacetylation 
restores the positive charge, allowing the chromatin to condense into a tightly 
supercoiled, transcriptionally silent conformation, precluding the access of transcription 
factors to the DNA and inevitably repressing transcription (4, 133).  
4a.ii. DNA Methylation 
DNA methylation, another mode of epigenetic modulation, involves the addition 
of a methyl group to cytosine at the C5-pyrimidine position. This is facilitated by DNA 
methyltransferases (DNMT1, 3a, and 3b) (135, 136). This post-synthetic addition alters 
the appearance of the major groove of DNA, affecting the interactions with DNA binding 
proteins. The sites of methylation are in the CpG Islands. These islands are found in 
association with genes, usually in the promoter regions (137, 138). This modification 
renders a gene transcriptionally silent as gene-specific methylation patterns correlate 
inversely with gene activity (139). Methylation also mediates the formation of a 
multiprotein repression complex that results in the recruitment of HDACs (140, 141), 
thus promoting another mode of transcriptional repression. 
Aberrations in methylation and histone deacetylation coupled with HDAC2 
overexpression has been implicated in multiple cancers. Through immunohistochemistry, 
Song et al.(5) observed an increase in HDAC2 expression in association with aggressive 
tumor growth in human gastric cancer specimens. Aberrant recruitment of HDACs has 
also been noted in acute myelogenous leukemia (142). With regard to 
gastroenteronpancreatic neuroendocrine tumors, Chan et al. noted distinct methylation 
patterns in the promoter regions of certain genes including p14, p16, cox2, and the 
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estrogen receptor. Specifically in carcinoids, methylation of the p16 promoter region 
correlated with metastatic status. 
A major difference between genetic and epigenetic events is that latter may be 
reversed by chemical agents (143). Current therapeutic strategies for certain malignancies 
include DNA methylation inhibitors and HDAC inhibitors (144, 145). These strategies 
have been used in treating leukemias (146) and lymphomas (147). Trichostatin A (TSA) 
and Sodium Butyrate (SB) (HDAC inhibitors) were found to dramatically induce 
apoptosis and down-regulate bcl-2 expression in B cell lymphomas with t(14;18) 
translocations (148). 5-azacitidine, a DNA methylation inhibitor, has been used in the 
treatment of acute myelogenous leukemia (149) and of refractory anemia in patients with 
myelodysplastic disorders (150) with promising results. HDAC and DNA methylation 
inhibitors may also be of utility in solid organ tumors (151, 152).  
 
5. A Focus on the MTA1 Complex: Histone Deacetylase 2 and Metastasis 
Associated Protein 1 
5a. Histone Deacetylase 2 (HDAC2) 
Histone Deacetylase 2 (HDAC2) is a major component of normal and aberrant 
epigenetic processes. Increased expression has been noted in gastric (5) and colorectal (6) 
carcinomas. Most notably, the overexpression of this enzyme has been associated with 
aggressive disease course in gastric cancer patients (5).  
 Located on 6q21 (153), the gene for HDAC2 encodes a 488 amino acid protein 
that localizes to the nucleus. There are 4 major groups of histone deacetlyases. Class I 
includes HDAC1, HDAC2, HDAC3, and HDAC8. Class II includes HDAC4, HDAC5, 
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HDAC6, and HDAC7 (154). The Sir2 (155) and maize HD2 (156) families complete the 
list. 
5a.i. Function: 
 HDAC2 is an enzyme capable of removing an acetyl-group from the N-terminal 
lysines of histone proteins. This acetylation leads to the deneutralization of the positive 
histone charge and results in a change in DNA conformation. This process serves as a 
means of transcriptional repression. An increase in local concentrations of HDAC2 has 
been noted in association with hypoacetylated chromatin (157). 
Histone deacetylation can be triggered by DNA methylation when HDAC2 is a 
part of the Nucleosome Remodeling and Deacetylating (NuRD) complex, which contains 
MTA2, HDAC1/2, RbAp48/p46 (histone binding proteins), and MBD3 (methyl-CpG-
binding domain-containing protein 3- mediates the association of MTA2 with the core). 
This NuRD complex interacts with Methylation Binding Domain 2 (MBD2) and directs 
the complex to methylated DNA. This provides a means expression regulation of 
methylated DNA via histone alternation (158).  
HDAC2 is also found in complex with MTA1, the second protein of focus in our 
investigation. This relationship will be further discussed in the next section. 
5a.ii. Regulation: 
In colorectal cancer models, HDAC2 expression is regulated by the APC 
(Adenomatosis Polyposis Coli)/Beta-Catenin pathway. The loss of the APC gene resulted 
in increased HDAC2 expression. Through chromatin immunoprecipitation, c-Myc was 
found bound to the HDAC2 promoter region. This is proposed to directly upregulate 
HDAC2 expression (6).  
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5b. Metastasis Associated Protein 1 (MTA1) 
Metastasis associated protein 1 (MTA1) may have a pivotal role in the aggressive 
nature and the metastatic status of many different tumors. Over-expression of MTA1 
mRNA and protein correlates with tumor invasion and metastasis in various tumors 
including breast (11, 159), hepatocellular (12), esophageal (13), gastric and colorectal 
carcinomas (14). With regards to breast cancer, MTA1 overexpression is linked to a high 
risk of recurrence. These cases, however, have favorable responses to systemic therapies 
(160). 
Located on 14q32.3 (161), the MTA1 gene encodes a 702 amino acid protein that 
is localized to the nucleus. In 2002, Kumar et al. identified a shorter splice variant of 
MTA1, MTA1s (430 amino acids). Localized to the cytoplasm, this protein is involved in 
the sequestration of Estrogen Receptor-alpha (ERα) in the cytoplasm. MTA1s expression 
is increased in human breast tumors with no or low nuclear ER (162). 
5b.i. Function: 
MTA1 has been implicated in transcriptional repression, chromatin remodeling, 
cellular growth, and cell motility.  
5b.i.a. Transcriptional Repression: 
 MTA1 represses transcription of genes under the control of estrogen-responsive 
elements (EREs). It functions via direct binding to ERα (8), direct binding to ERα 
coactivators (163, 164), or via the recruitment of HDAC2 (7). 
Mazumdar et al. found that, by binding to the activation domain of ERα, MTA1 
acts as a potent corepressor of the transcription of ERE-associated genes. Mazumdar et 
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al. concluded that ERα-mediated transcription was a target of MTA1 as it acted as a 
corepressor (8). In 2004, Moon et al. reported that in hepatocellular carcinoma, MTA1 
expression correlated inversely with the presence of nuclear ERα. The presence of this 
protein was also associated with increased tumor size and increased angioinvasion (12). 
With regards to indirect repression of ERE-controlled genes, MTA1 may work 
through the nuclear receptor co-activator designated as NRIF3. Normally, this protein 
acts as an ER coactivator, resulting in the hyperstimulation of ER transactivation. The 
binding of MTA1 to NRIF3 results in transcriptional repression of genes under the 
control of EREs (163). Similar repressive activity was previously found with MiCoA 
(MTA1-interacting coactivator), a protein with similar ER-coactivator functions (Mishra 
et al., 2003) (164).  
5b.i.b. Chromatin Remodeling: 
MTA1 has been found in complex with HDAC1/HDAC2, Mi-2beta, and 
RbAp48/p46, forming the Nucleosome Remodeling and Deacetylating (NURD) complex 
(7). Mi-2beta is a dermatomyositis-associated autoantigen (165) that may have helicase 
properties (166). RbAp48/p46 are histone binding proteins (167). (This complex is unlike 
the previously mentioned NuRD complex involving MTA2.) 
An investigation by Toh et al. (13) demonstrated MTA1’s association with 
histone deacetylase activity. Through immunhistochemistry, the group found an inverse 
relationship between MTA1 and the acetylation status of H4 in cases of esophageal 
squamous cell carcinoma (13). Mazumdar demonstrated the repression of MTA1-
mediated transcription through the use of Trichostatin A, a histone-deacetylase inhibitor 
(8). 
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5b.i.c. Cellular Growth: 
MTA1 may induce abnormal tissue growth. In a study of transgenic mice, 
Bagheri-Yarmand et al. (9) (2004) showed that MTA1 was involved in increased 
proliferation of ductal and alveolar epithelial cells. The administration of antisense 
oligonucleotides specific for MTA1 prohibited the rapid growth of human breast cancer 
cells with high MTA1 expression (168). This protein may be a mediator of aggressive 
breast cancer development and progession. 
5b.i.d. Cell Motility: 
Multiple investigations have demonstrated MTA1’s effect on cell motility, 
potentially mediating the movement and invasion of metastatic cells. Utilizing the 
PANC-1 pancreatic carcinoma cell line, Hofer et al. (10) found that, by inducing MTA1 
overexpression through the transfection of an EGFP-MTA1 fusion protein, cellular 
motility was markedly enhanced. There was also a concomitant increase in the invasive 
penetration of epithelial barriers by the cells with actual modulation of the cytokeratin 
filament system. These findings suggest an indirect role for MTA1 in the enhancement of 
cell motility, thus potentiating the metastasis of tumor cells (10). MTA1 also enhanced 
the migration and invasion of immortalized human keratinocytes. Mahoney et al. (2002) 
purported that MTA1 expression may depend, in part, on the activation of the Epidermal 
Growth Factor Receptor (EGFR). Similar to the investigations of Mazumdar et al. (2001), 
this group suggested MTA1 enhancement of anchorage-independent cell survival (169). 
5b.ii. Regulation: 
In 2001, Mazumdar et al. suggested that the transcription of this gene may be 
under the control of the heregulin/HER2 pathway. This pathway has been implicated in 
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the suppression of ERE-driven transcription- thus decreasing the estrogen-responsiveness 
of a cell. Through in vitro studies using ERα positive breast cancer cells, Mazumdar 
found that stimulation with heregulin (HRG) led to increased expression of MTA1. 
Stimulation of cells with HRG also led to the suppression of histone acetylation and 
increased deacetylase activity (8).  
In the fall of 2005, Zhang et al. (170) published a key regulatory finding. c-MYC, 
an oncoprotein that is highly expressed in many cancers (171-173), may be the upstream 
regulatory element involved in the regulation of MTA1 expression. Through cell lines 
transformed with a c-MYC/ER fusion protein and a mouse animal model, this group 
found a direct correlation between c-MYC and MTA1 expression. This may occur 
through the direct recruitment of histone acetyltransferases (HAT) to the MTA1 promoter 
region mediated by MbII, an element in the N-terminal transactivation domain of c-MYC 
(174, 175) that facilitates the assembly of HAT complexes. These complexes acetylate 
the lysine of histones, thus neutralizing the positive charge and changing the chromatin 
conformation. 
Overall, it appears that MTA1 expression may be under the control of the 
HRG/HER2 pathway and it may also be mediated by c-MYC, an oncoprotein highly 
expressed in multiple carcinomas. Further analysis of MTA1’s promoter region may lead 
to the discovery of other transcriptional control elements. 
5c. HER2, ERα, and GI Carcinoids: 
One of the paradigms of successful endocrine-targeted therapy in tumor disease is 
breast cancer (176). The exploration of endocrine pathways in breast cancer has led to the 
discovery of successful endocrine-targeted therapies such as Tamoxifen (177) and 
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Herceptin (178). These therapies, operating via the ERα and HER2 (neu or erb-B2) 
pathways, respectively, have proven successful in the inhibition of cell proliferation. The 
logic behind these therapies is based upon a correlation between receptor presence and 
clinical profiles. HER2, a member of the epidermal growth factor receptor family, is 
genetically amplified and over-expressed in aggressive breast cancers and high levels are 
associated with poor prognosis, particularly in node-positive breast carcinoma patients 
(179) In contrast, the presence of ERs typically indicates slower-growing tumors that 
may be amenable to hormonal manipulation (180). 
The description of the existence of ERα on carcinoid tumors (181) eventually led 
to the exploration of Tamoxifen therapy in these tumors. One group reported repression 
of carcinoid syndrome symptoms with tamoxifen therapy. The therapeutic benefits, 
however, diminished one year later as the symptoms returned (182). Later reports 
presented similar negative results (183, 184). Despite these data, estrogen and its receptor 
may have a role in carcinoid tumors. Recent studies by Chan et al. (185)  reported 
promoter methylation of the ERα gene in 63% (10 of 16) GI carcinoid tumors. Overall, 
evidence for the presence of the ERα in gastrointestinal (GI) carcinoid tumors, however, 
remains equivocal while the biological role of estrogen in gastrointestinal carcinoid 
tumor proliferation is controversial. Conversely, HER2/neu amplification has been 
identified in 4 out of 10 carcinoid tumors of the gut; three of which were invasive or 
metastatic (186). Although the presence of HER2/neu has been suggested, the role of 
these receptors and their respective pathways remains to be explored in GI carcinoids. 
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6. A Statement of Purpose 
The aims of the current study were to examine the biological and clinical 
significance of the MTA1/HDAC2 complex in Small Intestinal Carcinoids. Techniques 
utilized in this investigation include cDNA Microarray, Pathway Analysis, Q-RT-PCR, 
Tissue Microarray, and Enzymatic Assays. 
An interrogation of HDAC2 and MTA1 genetic and protein expression, coupled 
with functionality, will enable the delineation of an association between epigenetic 
modulation and SIC development and progression. This analysis may also aid in the 
classification of malignant carcinoids. In addition, the presence of such a relationship 
may indicate the potential therapeutic utility of HDAC inhibitors in the treatment of SIC. 
The examination of ERα and HER2/neu could identify subtypes of SICs that may 
respond to endocrine-targeted therapies, while the exploration of the relationship between 
the ERα and HER2 pathways with MTA1 may provide insight into the tumorigenesis and 
acquisition of malignant traits in SICs. To delineate the relevance of these pathways in 
SIC, alterations in gene and protein expression of ERα, Trefoil Factor 1 (TTF1/pS2- a 
downstream gene under the control of estrogen (187, 188)) and HER2/neu in SICs were 
measured. Since ERα, HER2, and MTA1 expression have been previously well-
characterized in breast tissue, both normal and cancerous breast specimens were used as 
controls. 
In addition to HER2 pathway analysis in the upregulation of MTA1 gene 
expression, we analyzed the promoter region of this gene, to identify other potential 
mediators of transcriptional activation. This was undertaken using a computer to search 
for the presence both of transcription factor element sites and CpG methylation islands. 
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To investigate the promoter region, primers were developed to isolate the region for 




1) Aberrant transcriptional regulation is central to SIC tumorigenesis and the 
development of metastasis.  
2) MTA1 and HDAC2 proteins, in epigenetic processes, have functional roles in 
SIC development and may aid in the classification of SIC subtypes, thus 
facilitating improved diagnosis and prognostication. 
3) There will be an inverse relationship between MTA1 expression and ERα-
controlled gene products such as TFF1.  
4) The Heregulin/HER2 pathway is involved in the upregulation of SIC MTA1 
expression.  
5) CpG island (de)methylation may be a cause of MTA1 overexpression in SICs. 
 
To summarize, we hypothesize that aberrant epigenetic functions, mediated by the 
MTA1/HDAC2 complex, are important for SIC development and malignant progression. 
 
8. METHODS 
8a. Tissue Specimens 
8a.i. Construction and Processing of Small Intestinal Carcinoid TMA. Formalin-
fixed paraffin-embedded tissue blocks containing 101 GI carcinoids (stomach: n=5; 
duodenum: n=4; small bowel and ileocecal: n=55; appendix: n=25; colon: n=12) were 
retrieved, along with the corresponding H&E-stained slides, from the archives of the 
Yale University School of Medicine Department of Pathology. Blocks were stored 
under ambient conditions within a temperature range of 18-37°C. To ensure uniformity 
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of sectioning, older paraffin blocks were melted and re-embedded using modern-day 
plastic cassettes. Areas of carcinoid, areas of normal tissue, lymph node metastases and 
liver metastases were identified by Dr. R.L. Camp and marked for subsequent retrieval 
and analysis. Core biopsies 0.6 mm in diameter were taken from each donor block and 
arrayed into a recipient paraffin block (45 mm x 20 mm) using a tissue puncher/arrayer 
(Beecher Instruments, Silver Spring, MD) as described by Xie et al.(189) The array 
contained 101 cases of primary GI carcinoids (55 of which were small intestinal) and 
matched normal tissue, 15 lymph nodes and 7 liver metastases diagnosed between 1965 
and 2003. The array was created by Lori Charette of the Yale Cancer Center Tissue 
Microarray Facility. For the SIC patients, follow-up information was available (median 
follow-up: 103 months, range: 29-264 months) for all small intestinal carcinoid patients 
[Table 1]. 
 
Table 1. Characteristics of carcinoid patients (n = 55) on the tissue microarray 















Small bowel (n = 55) 19:21 62 (40-89) 8/38 21/38 103 (29-264) 5:33 
ANED = Alive no evidence of disease; AWD = Alive with disease. *p=0.00043, **p<0.00001 
 
 
8a.ii. Fresh Tissue. Tumor tissue from seven patients (M:F = 6:1; median age [range] = 
58 yr [40-73]) diagnosed with GI malignancies were collected for this study [Table 2]. 
Seven small bowel EC carcinoids (n=7) were examined; four patients had matched 
normal mucosa (n=4). Tissue was collected from the Department of Surgical Pathology 
(Yale University School of Medicine) and from the Cooperative Human Tissue Network 
which is funded by the National Cancer Institute. None of the patients had received 
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therapy (surgery or somatostatin analogs) prior to tissue procurement. Paired normal 
tissue samples were also obtained from adjacent, macroscopically normal, non-tumor 
mucosa in seven patients. In addition tumor (n= 5) and normal (n=5) breast tissue were 
used as controls (Courtesy of Dr. D. Lannin and the Yale University Department of 
Pathology). None of the breast patients had received therapy (radiation or 
chemotherapeutics) prior to tissue procurement. Fresh tissue was acquired by M. 
Zikusoka. 
 
Table 2. Carcinoid tumor patients and specimens 
 
No. Sex Age# Site of primary tumor Tissue analyzed Liver metastasis LN metastasis
1.* F 40 Small Bowel Liver metastasis/liver Y N 
2.* M 73 Small Bowel EC carcinoid/Normal Y Y 
3.* M 48 Small Bowel EC carcinoid/Normal - - 
4. M 64 Small Bowel EC carcinoid Y Y 
5. M 58 Small Bowel EC carcinoid Y Y 
6.* M 73 Small Bowel EC carcinoid/Normal N Y 
7. M 55 Small Bowel EC carcinoid - Y 
* normal tissue available, # age at time of procedure, LN = lymph node, - = no data available
 
 
8b. Molecular Biological Techniques 
8b.i. cDNA Microarray Construction. Material from 12 small intestinal tissue blocks 
(n=11 patients; normal small intestinal mucosa: n=4, malignant small intestinal 
carcinoids [that had clinical evidence of liver and lymph node metastases]: n=8) was 
examined using Affymetrix™ GeneChip® (Santa Clara, CA) analysis. Tissue was micro-
dissected and histologically verified (by Dr. R.L. Camp) to be free of non-tumor cells. 
Total RNA was isolated from each sample using the Rneasy® kit (Qiagen). Target 
cDNAs were generated and hybridized to human HU133A GeneChip® (Affymetrix, 
Santa Clara, CA). The intensity was equally scaled for each chip (intensity = 500) and 
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genes normalized using the RMA algorithm. Thereafter, differences in gene expression 
between tumors and normal mucosa were examined using GeneSpring® software 
(Agilent Technologies, Palo Alto, CA). Analysis was performed by Dr. M. Kidd and Dr. 
S. Mane. 
8b.ii. Pathway Analysis. Ingenuity® Pathway Analysis (Redwood City, CA) was used 
to identify gene networks of interest. This approach allows identification and biological 
exploration of gene networks of potential therapeutic relevance that are significantly 
expressed in gene expression data. These pathways are scored, with scores >2 having at 
least a 99% chance of not being generated by random chance alone (Ingenuity ® Pathway 
Analysis manual). Analysis performed by Dr. M. Kidd. 
8b.iii. RNA Isolation. Total RNA was isolated from fresh frozen small intestinal 
carcinoid tumor tissue (n=7), fresh frozen breast tumor tissue (n=5), normal SI mucosa 
(n=4), and normal breast tissue (n=5) using TRIzol reagent (Invitrogen, Carlsbad, CA) 
using the manufacturer’s guidelines. RNA was dissolved in DEPC water, measured 
spectrophotometrically and an aliquot analyzed on a denaturing gel using electrophoresis 
to check the quality of RNA isolated. (M. Kidd and M. Zikusoka) 
8b.iv. Q RT-PCR. ERα, TFF1, HER2/neu, HDAC2, and MTA1 message was 
quantitatively measured in the 11 samples. PCR was performed using the ABI 7900 
Sequence Detection System. Total RNA from each sample was subjected to reverse 
transcription using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, CA) following the manufacturers suggestions. Briefly, 2μg of total RNA in 50 μl of 
water was mixed with 50 μl of 2X RT mix containing Reverse Transcription Buffer, 
dNTPs, random primers and Multiscribe Reverse Transcriptase. RT reaction was carried 
 36
out in a thermal cycler for 10 min at 25°C followed by 120 min at 37°C. Real time PCR 
analysis was then performed. cDNA in 7.2 μl of water was mixed with 0.8 μl of 20 x 
Assays on Demand® primer (Applied Biosystems, Foster City, CA) (ERα = 
Hs00174860, TFF1 = Hs00170216, HER2/neu = Hs00170433, HDAC2 = Hs00231032, 
MTA1 = Hs00183042, GAPDH = Hs99999905) and probe mix, 8 μl of 2x TAQMAN 
Universal Master mix in a 384 well optical reaction plate. The following PCR conditions 
were used: 50°C for 2 min, then 95°C for 10 min, followed by 40 cycles at 95°C/0.15 
min and 60°C /1 min. A standard curve was generated for each gene using cDNA 
obtained by pooling equal amounts from each sample (n=11). The expression level of 
target genes was normalized to internal GAPDH. Data was analyzed using Microsoft ® 
Excel (2002) and calculated using the relative standard curve method (ABI, User Bulletin 
#2). (M. Kidd and M. Zikusoka) 
8b.v. Tissue microarray immunostaining, image acquisition and data analysis. For 
antigen retrieval purposes, tissue microarray slides were immersed in citrate buffer (10 
mm sodium citrate, pH 6.0), and subjected to 1 x 10 min high temperature-high pressure 
treatment followed by the treatment with 0.3% H2O2 in methanol for 30 min at 37°C to 
inactivate endogenous peroxidase. Slides were incubated for 24 hr at 4°C with primary 
antibodies diluted in Tris-buffered saline containing BSA. Primary antibodies used 
included mouse monoclonal anti-ERα (1:500; DAKO Corp., Carpinteria, CA), mouse 
monoclonal anti-HER2/neu (1:500 and 1:5,000; DAKO Corp., Carpinteria, CA), mouse 
monoclonal anti-TFF1 (pS2, 1:500, NovaCastra. New Castle, England), mouse 
monoclonal anti-HDAC2 (1:200, Santa Cruz Biotech, Santa Cruz, CA), and mouse 
monoclonal anti-MTA1 (1:100, Santa Cruz Biotech, Santa Cruz, CA). Goat anti-mouse 
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antibody conjugated to a horseradish peroxidase-decorated dextran polymer backbone 
(Envision; DAKO Corp, Carpinteria, CA) was used as a secondary reagent. For 
automated analysis, tumor cells were identified by the use of a fluorescently tagged 
anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp, Carpinteria, CA), nuclei were 
visualized by 4’,6-diamidino-2-phenylindole (DAPI), and targets visualized with a 
fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, MA). 
Antibody expression on the carcinoid tissue microarray was determined using an 
automated tissue microarray reader controlled by 2 observers (M. Kidd (M. Zikusoka) and 
R.L. Camp). Automated image acquisition and analysis using AQUA was developed by 
Dr. R.L. Camp (190). In brief, monochromatic, high-resolution (1024 x 1024 pixel; 0.5-
mm) images were obtained of each histospot. Areas of tumor from stromal elements were 
distinguished by creating a mask from the cytokeratin signal. Coalescence of cytokeratin 
at the cell surface localized the cell membranes, and DAPI was used to identify nuclei. 
The target signal from the membrane area of tumor cells was scored on a scale of 0–255 
and expressed as signal intensity divided by the membrane area. Histospots containing 
<10% tumor, as assessed by mask area (automated), were excluded from further analysis. 
Previous studies have demonstrated that the staining from a single histospot provides a 
sufficiently representative sample for analysis (191). Disc scores from the same tumor 
were averaged to produce a single score. (M. Kidd and M. Zikusoka) 
8b.vi. Indirect HDAC2 Activity Assessment. HDAC2 activity was indirectly evaluated 
using immunohistochemical techniques. Amounts of acetylated Histone 2B and 
deacetylated Histone 2B were analyzed in contrast to HDAC2 expression. For antigen 
retrieval purposes, tissue microarray slides were immersed in citrate buffer (10 mm 
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sodium citrate, pH 6.0), and subjected to 1 x 10 min high temperature-high pressure 
treatment followed by the treatment with 0.3% H2O2 in methanol for 30 min at 37°C to 
inactivate endogenous peroxidase. Slides were incubated for 24 hr at 4°C with primary 
antibodies diluted in Tris-buffered saline containing BSA. Primary antibodies used 
included mouse monoclonal anti-H2B (1:200, Santa Cruz Biotech, Santa Cruz, CA) and 
mouse monoclonal anti-acetylated H2B (1:500, Santa Cruz Biotech, Santa Cruz, CA). 
Goat anti-mouse antibody conjugated to a horseradish peroxidase-decorated dextran 
polymer backbone (Envision; DAKO Corp, Carpinteria, CA) was used as a secondary 
reagent. For automated analysis, tumor cells were identified by the use of a fluorescently 
tagged anticytokeratin antibody cocktail (AE1/AE3; DAKO Corp, Carpinteria, CA), 
nuclei were visualized by 4’,6-diamidino-2-phenylindole (DAPI), and targets visualized 
with a fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, 
MA). Antibody expression on the carcinoid tissue microarray was determined using an 
automated tissue microarray reader controlled by 2 observers (M. Kidd (M. Zikusoka) 
and R.L. Camp). Automated image acquisition and analysis using AQUA was developed 
by Dr. R.L. Camp(190). Disc scores from the same tumor were averaged to produce a 
single score. Data was then compared with regards to acetylation status and HDAC2 
staining patterns. (M. Kidd, R.L. Camp, M. Zikusoka, and G. Eick) 
8b.vii. HDAC Activity Assay. HDAC proteins were isolated from SIC tumor samples 
and normal SI mucosa. Samples were ground to a fine powder using mortar and pestel 
under liquid nitrogen and immediately resuspended in RIPA lysis buffer including 
0.1mM phenylmethylsulfonyl fluoride and freshly added protease inhibitor cocktail 
(Roche, Indianapolis, IN). After homogenization by syringe shearing, samples were 
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centrifuged at 10,000g for 15 min at 4°C. The resulting supernatant was used for the 
HDAC assay. Enzyme activity in normal and tumor samples was measured using the 
HDAC Colorimetric Activity Assay kit (Biomol) following the protocol provided by the 
supplier. The assay is based on cleavage by HDAC1/2 of an acetylated lysine side chain 
in the Colorimetric Histone Deacetylase Lysyl Substrate. The optimal conditions were 
first established (60 minute incubation period; substrate concentration = 0.6mM, protein 
concentration = 25mg total protein/experiment) and reaction kinetics of HDAC activity 
was determined in pooled total protein samples (n=4) from isolated from SIC tumor and 
normal bowel samples. The Km of the enzymatic activity was ~0.45mM; the apparent Km 
of HDAC is 0.42mM for HeLa nuclear extracts (Biomol kit insert). This demonstrates 
that HDAC activity can be measured in proteins extracted from fresh-frozen surgical 
samples. The specificity of HDAC activity was demonstrated by inhibition with 1µM 
Trichostatin A – a HDAC Class I and II inhibitor. In these experiments, HDAC activity 
was measured in triplicate in each sample. Samples included normal mucosa (n=3) and 
small intestinal carcinoid (n=4). Comparisons were made using 2-way ANOVA 
(p<0.05). (M. Kidd, M. Zikusoka and G. Eick) 
8b.viii. MTA1 Promoter Region Analysis. The promoter sequence for the MTA1 gene 
was examined using Chromas® version 2.31 (Technelysium Ltd). The promoter region 
was analyzed for the presence of response elements which may be responsible for the 
control of transcription of the MTA1 gene. The search included TATA boxes (TATA), 
SP1 promoter sites (GGGCGG), c-Myc (CACGTG), c-Fos/c-Jun (TGACTCA & 
TGAGTAA), GATA (AGATA/TGATA), Retinoic Acid Receptor (GTTCAC), CREB 
(TGACG), and E2F (TTTCGCGGCAAA) and CpG methylation islands. TESS: 
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Transcriptional Element Search System (www.cbil.upenn.edu/tess) was utilized to find 
the nucleotide patterns of the aforementioned transcription elements. (M. Kidd and M. 
Zikusoka). 
8b.ix. Isolation of MTA1 Promoter Region. After the analysis of the promoter region of 
the MTA1 gene, the following primers were designed by visual analysis in order to isolate 
the promoter region: MNZF1: CCG CTC CAT GTC CTA CAG AG, MNZR: CTG GTA 
GAT CCT CCC CTG GT, MNZF2: GAG GAT CTA CCA GGG GGT TC, MNZR2A: 
CTC CTG CTC CCA GAC CGG CA, MNZR2B: CAA AAC TCC TGC TCC CAG AC 
and MNZR2C: CTC CGA CCC TGT ACA TGT TGG CG. All primers were constructed 
at the W.M. Keck Oligonucleotide Synthesis Facility at Yale University. PCR was used 
to amplify the MTA1 promoter region. Total DNA from samples (normal liver, gastric 
carcinoid, SIC with liver metastasis, gastrinoma with lymph node metastasis) was 
extracted using standard phenol/chloroform methods after samples were ground to a fine 
powder using mortar and pestel under liquid nitrogen. Each reaction tube contained 2μL 
genomic DNA in 18.9μL H2O, 2.5μL 10X buffer, 1.5mM MgCl2, 0.5μL dNTPs, 0.5μL 
forward primer, 0.5μL reverse primer, and 0.1μL Taq polymerase. PCR Core Kit (Roche 
Applied Science, Indianapolis, IN). Using primer combinations of MNZF1/R1, 
MNZF1/R2C, MNZF2/R2A, MNZF2/R2B, MNZF2/R2C, PCR was carried out in a 
thermal cycler for 35 cycles (Denaturing Temperature: 95 degrees, 30 seconds; 
Annealing Temp: 55degrees, 45 seconds; Extension Temperature: 72 degrees, 1 minute). 
Expected product lengths were 848, 1259, 800, 805, and 424 bases, respectively. 
MNZF1/R2A and MNZF1/R2B primer combinations were not pursued due to the 
excessive length of expected products (1635 and 1640 bases, respectively). Gel 
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electrophoresis was used to confirm product presence and length. Sequences of the PCR 
products were produced by W. M. Keck DNA Sequencing Facility at Yale University. 
The Basic Local Alignment Search Tool (Blast-N)® program provided by the National 
Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov) was used to was 
used verify product identities. (M. Zikusoka and G. Eick) 
8b.x. Statistical analysis. Results of Q RT PCR and AQUA were expressed as mean ± 
SEM; n indicates the numbers of patients in each study group. Statistical significance was 
calculated by the two-tailed Student’s test for paired and unpaired values as appropriate, 
with a probability of < 0.05 representing significance. 
 
9. RESULTS 
9a. Gene Expression Profile Analysis: 
Affymetrix GeneChip analysis of SIC identified 1709 genes significantly altered in 
malignant SIC tumors compared to normal small intestinal mucosa. Hierarchical 
clustering of 12 Affymetrix chips which included normal small intestinal mucosa (n=4) 
and malignant SIC tumors (n=8) was performed at the W.M. Keck Affymetrix Facility at 
Yale University, revealing a clear genetic distinction between gene expression profiles of 
normal mucosal and tumor tissue. Ingenuity Pathway Analysis allowed the delineation of 
gene networks with significant differences in gene expression between normal and tumor 
tissue prominent aberrations in the gene profile analysis. The highest scoring pathway 
was the HDAC-related transcriptional repression pathway [FIGURE 2]. These results led 














Fig 2. Hierarchical clustering of 12 Affymetrix chips including 
normal small intestinal mucosa (N; n=4) and malignant small 
intestinal carcinoid tumors (T; n=8). There is a clear separation 
between normal mucosal genes and tumor genes. Expression levels 





9b. Message Expression Analysis through Q RT-PCR: 
Real-time PCR analysis was undertaken using Assays on Demand (Applied Biosystems) 
products on cDNA from seven small bowel carcinoids and four macroscopically normal 
adjacent mucosal samples to quantitatively measure the levels of ERα, TFF1, HER2/neu, 
HDAC2, and MTA1 mRNA expression. We used primary breast tumor tissue as controls 
and obtained the following message profiles: ERα- 2.518±1.05, MTA1- 0.5±0.26, TFF1- 
0.19±0.09, HER2- 0.5±0.18. Levels of all these factors were increased compared to the 
normal breast specimens: ERα- 0.088±0.035, MTA1- 0.38±0.21, TFF1- 0.00, HER2- 
0.12±0.06.  
9c. Tissue Microarray: 
The clinical characteristics of the fifty-five SIC patients are given in Table 1 (See page 
24). A comparison of normal small intestinal mucosa and the primary tumors of patients 
with and without disseminated disease (i.e. presence of lymph node or liver metastases) is 
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indicated below. No statistically significant differences in these characteristics were 
noted except in the distribution of lymph node involvement (χ2=20.4, p<0.0005) and 




Fig. 3. MTA1 expression. Triple staining of small 
intestinal carcinoid histospot on tissue microarray. 
Green = cytokeratin (FITC). Blue = nuclear-staining 
(DAPI). Red = MTA1 staining (Cy5). Purple = 








9d. MTA1 in Small Intestinal Carcinoids 
9d.i. Q-RT-PCR Analysis: 
We observed elevated message levels of MTA1 in the primary and metastatic SIC tumor 
samples compared to normal tissue (3.58±1.5 and 5.96±2.4 vs. 1.68±0.16; p=0.05 and 
p<0.05). [FIGURE 4A] 
9d.ii. Tissue Microarray Analysis: 
An examination of the MTA1 stained histospots from the 55 SIC patients on the TMA 
demonstrated MTA1 expression. Differences in MTA1 expression in local (75±12) and 
disseminated (78±1) SIC specimens compared to normal (3±1) were of statistical 
significance (p=0.05, p<0.01). A comparison of the AQUA scores of SIC specimens in 
patients with local vs. disseminated disease (Mean AQUA Score: 75±12 vs. 78±1) is not 




Fig. 4. Graphical presentation of Q-RT-PCR and AQUA Analysis for MTA1 in Small Intestinal 
Carcinoids. (A) Mean mRNA expression levels increased as the small intestinal specimen progressed 
from normal (1.68±0.16) to primary (3.58±1.5) to metastatic (5.96±2.4) status. The changes were of 
statistical significance (*p=0.05, #p<0.05).  (B) Mean protein expression levels increased significantly 
in the primary tumors of patients with both local (75±12) and disseminated disease (78±14) compared 
to normal (3±1). These changes were also of statistical significance (#p<0.05, #p<0.05).  
9e. HDAC2 in Small Intestinal Carcinoids 
9e.i. Q-RT-PCR Analysis: 
We observed elevated message levels for HDAC2 in the primary and metastatic SIC 
tumor samples compared to normal tissue (2.0±0.8 and 4.1±0.6 vs. 0.07±0.02; p<0.003 
and p<0.003). [FIGURE 5A] 
9e.ii. Tissue Microarray Analysis: 
An examination of the HDAC2 stained histospots from the 55 SIC patients on the TMA 
demonstrated HDAC2 expression. Differences in HDAC2 expression in local (712±101) 
vs. disseminated (762±105) SIC specimens compared to normal mucosa (524± 81) are of 
statistical significance (p<0.05). A comparison of the AQUA scores of SIC specimens in 
patients with local vs. disseminated disease (712±101 vs. 762±105) was not of statistical 




Fig. 5. Graphical presentation of Q-RT-PCR and AQUA Analysis for HDAC2 in Small Intestinal 
Carcinoids. (A) Mean mRNA expression levels increased as the small intestinal specimen progressed 
from normal (0.07±0.02) to primary (2.0±0.8) to metastatic (4.1±0.6) status. The changes were of 
statistical significance (&p<0.003, &p<0.003).  (B) Mean protein expression levels increased 
significantly in the primary tumors of patients with both local (712±101) and disseminated disease 
(762±105) compared to normal (524±81). These changes were also of statistical significance (#p<0.05, 
#p<0.05). 
 
9e.iii. HDAC2 activity in SIC cells: 
The HDAC activity assay utilized protein samples from both tumor samples and normal 
intestinal mucosa. The assay [Figure 6] demonstrated a significant elevation in HDAC 
activity in SIC samples (4-fold; p<0.03) compared to normal mucosa. The specificity of 
HDAC activity was demonstrated by inhibition with 1µM Trichostatin A (TSA). This 
resulted in a 70-80% inhibition of HDAC activity in normal mucosa and SICs. Normal- 
0.08, Normal with TSA- 0.04, SIC- 0.32, SIC with TSA- 0.081. A comparison of normal 
vs. SIC HDAC activity had a p-value of <0.03. Of note, the HDAC colorimetric assay is 
not specific for HDAC2 since it also measures the activity of HDAC1 and SIRT1. 
Overall, the results demonstrate elevated HDAC activity in SICs, thus suggesting a role 




Fig. 6. HDAC Activity Assay. HDAC enzyme 
activity was measured via colorimetric assay. 
Activity is reflected as the amount of 
absorbance measured at 405 nm. Normal vs. 
SIC activity, p<0.03. NML=normal, SIC= 










9e.iv. Indirect Assessment of Histone Deacetylase 2 activity: 
HDAC2 activity was indirectly assessed through the measurement of HDAC2, acetylated 
H2B, and non-acetylated H2B using immunohistochemical techniques coupled with 
automated analysis (AQUA). Both H2B and acetylated H2B were localized in the 
nucleus. This investigation established a direct correlation with increased HDAC2 
presence with decreased acetylated H2B. The acetylated form of H2B was significantly 
decreased (p<0.05) in the SICs (Mean AQUA Score = 502±121) and their metastases 
(523±112) compared to normal mucosa (757±116) [Figure 7]. These data not only 
corroborate the HDAC2 activity assay results, but they suggest nuclear H2B 





Fig. 7. AQUA Analysis for Acetylated 
Histone 2B (H2B) in Small Intestinal 
Carcinoids. Mean protein expression levels 
were decreased in local (502±121) and 
disseminated (523±112) SIC samples compared 
to normal SI mucosa (757±116). *p<0.05. 
An examination of the acetylated H2B:non-acetylated H2B ratio in SICs compared to 
normal mucosa (1.43 vs. 1.74) [Figure 8] underscores the decreased acetylation level in 
tumor samples.  
 
Fig. 8. Ratios of nuclear histone 2B and 
acetylated histone 2B in normal vs. 
primary/disseminated SICs (1.74 vs. 
1.43). These data demonstrate that 
disease progression is associated with 
decreased acetylation of H2B. 
 
9f. HER2 in Small Intestinal Carcinoids 
9f.i. Q-RT-PCR Analysis: 
HER2 message levels were lower in both primary and metastatic SIC samples compared 




9f.ii. Tissue Microarray Analysis: 
No staining was noted for HER2/neu when the standard 1:5,000 dilution used routinely in 
identifying amplified HER2/neu in breast cancers was used. However, a dilution of 1:200 
detected HER2/neu positive cells on the TMA. This concentration identifies normal (non-
amplified) expression of HER2/neu in breast cancers and was used to evaluate expression 
levels in carcinoids. An examination of the HER2 stained histospots from the 55 SIC 
patients on the TMA demonstrated HER2 expression. Differences in local (9±1) and 
disseminated (6±0.5) SIC specimens as compared to normal (10±1) were not statistically 
significant. A comparison of the AQUA scores of SIC specimens in patients with local 
vs. disseminated disease (Mean AQUA Score: 9±1 vs. 6±0.5) was also statistically 
insignificant. [FIGURE 9B] 
 
 
Fig. 9. Graphical presentation of Q-RT-PCR and AQUA Analysis for HER2 in Small Intestinal 
Carcinoids. (A) Mean mRNA expression levels decreased as the small intestinal specimens progressed 
from normal (2.25±0.51) to primary (1.02±0.23) to metastatic (0.8±0.39) status. The changes were of 
statistical significance (*p=0.05, #p<0.05). (B) Mean protein expression levels, however, did not vary 
significantly when comparing the primary tumors of patients with both local (9±1) and disseminated 
(6±0.5) disease to normal small intestinal mucosa (10±1). NS= not significant. 
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9g. ERα in Small Intestinal Carcinoids 
9g.i. Q-RT-PCR Analysis:  
Message for ERα was elevated in both the primary and metastatic SIC samples compared 
to normal (5.71±3.1 and 3.01±1.4 vs. 0.49±0.19; p<0.05 and p<0.05.) [Figure 10A]. 
9g.ii. Tissue Microarray Analysis: 
An examination of the ERα stained histospots from the 55 SIC patients on the TMA 
demonstrated nuclear ERα expression. Differences between local (10.1±1) and 
disseminated (12±0.5) SIC specimens as compared to normal (11±0.5) were not of 
statistical significance. A comparison of the AQUA scores of patients with local vs. 
disseminated disease was also statistically insignificant. (Mean AQUA Score: 10.1±1 
vs. 12±0.5) [FIGURE 10B] 
 
Fig. 10. Graphical presentation of Q-RT-PCR and AQUA Analysis for ERalpha in Small 
Intestinal Carcinoids. (A) Mean mRNA expression levels varied between normal mucosa (0.49±0.19) 
and primary (5.71±3.1) and metastatic (3.01±1.4) small intestinal carcinoid samples. These changes 
were of statistical significance (#p<0.05, #p<0.05). (B) Mean protein expression levels between 
primary tumors samples of patients with local (12±0.5) or disseminated disease (10.1±1) vs. normal 






9h. TFF1 in Small Intestinal Carcinoids: 
9h.i. Q-RT-PCR Analysis: 
The investigation of TFF1 revealed decreased message levels in primary and metastatic 
SIC samples compared to normal (0.005±0.002 and 0.0059±0.0018 vs. 0.86±0.21; 
p=0.05 and p=0.05). [FIGURE 11A] 
9h.ii. Tissue Microarray Analysis: 
An examination of the TFF1 stained histospots from the 55 SIC patients on the TMA 
demonstrated TTF1 expression. Differences in local (83±5) and disseminated (75±4) SIC 
specimens as compared to normal (98±6) were of statistical significance (p=0.05, 
p<0.05). A comparison of the AQUA scores in the tumor specimens of patients with 
local vs. disseminated disease (Mean AQUA Score: 83±5 vs. 75±4) were not of statistical 
significance. [FIGURE 11B] 
 
Fig. 11. Graphical presentation of Q-RT-PCR and AQUA Analysis for TFF1 in Small Intestinal 
Carcinoids. (A) Mean mRNA expression levels decreased substantially in both primary (0.005±0.002) 
and metastatic (0.0059±0.0018) small intestinal carcinoid tumor samples compared to the levels found 
in normal small intestinal mucosa (0.86±0.21).  These changes were of statistical significance 
(*p=0.05, *p=0.05). (B) Mean protein expression levels were also decreased in primary tumor samples 
of patients with local (83±5) or disseminated disease (75±4) compared to normal small intestinal 




9i. Analysis of the MTA1 Promoter Region: 
The MTA1 promoter region contains c-Myc, c-Fos/c-Jun, c-Myb, and SP1 transcription 
response element site in addition to two CpG methylation islands. [Figure 12] 
 
LEGEND:  
Transcription Factor Response Elements:  
SP1……GGGCGG c-MYB……TAACGG 
c-Myc/Max……CACGTG TATA Box……TATA 
c-Fos/c-Jun……TGACTCA and TGAGTAA CpG Island Region……CG 
GATA……AGATA and TGATA Start Codon……ATG 
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9j. Isolation of the MTA1 Promoter Region: 
We attempted to isolate the MTA1 promoter region for future studies in promoter 
methylation patterns. Attempts to isolate the MTA1 promoter region were unsuccessful. 
Troubleshooting efforts included changes in the annealing temperature, use of thermal 
cycler touchdown mode, and changes in MgCl2 concentrations (1.5 mM vs. 2.5 mM). 
Although the approaches resulted in the identification of correctly sized bands, 
sequencing (W.M. Keck DNA Sequencing Facility) of these bands demonstrated that 
they were non-specific products.  
 
10. DISCUSSION 
10a. The Presence of MTA1 in SIC: MTA1 as a Marker of SIC Malignancy 
In both the Q-RT-PCR and AQUA studies, MTA1 expression was present and 
increased as the tissue progressed from normal to primary tumor to metastatic tissue. 
These results concur with previous reports of increased MTA1 levels and the association 
with a more aggressive tumor phenotype (12, 13, 159). MTA1 may be a marker of SIC 
malignancy. 
10b. The Presence of HDAC2 in SIC: HDAC2 as a Marker of SIC Malignancy 
In both the Q-RT-PCR and AQUA studies, HDAC2 expression was present and 
increased in tumor tissue as compared to normal small intestinal mucosa. These results 
concur with previously established data in gastric cancer (5). Increased expression of 
HDAC2 may be a marker of SIC malignancy. 
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10c. MTA1 Functionality in SIC 
A comparison of MTA1 and TFF1 mRNA expression in our SIC series reveals an 
inverse relationship. According to Mazumdar et al.’s model in the breast, MTA1 should 
affect the expression of genes under the control of EREs. Our data displays a functional 
role for MTA1 since with its overexpression, there is a concomitant decrease in TFF1 
expression. 
TFF1 is a protein product whose gene transcription is under the influence of 
estrogen (187, 188). Wang et al. previously reported TFF1 immunoreactivity in ileal 
carcinoids (192). The mRNA analysis of the TFF1 gene demonstrated dramatic decrease 
in expression levels. In both the primary and metastatic tissue samples, TFF1 expression 
was minimal. AQUA analysis also revealed decreased TFF1 protein expression in 
primary and metastatic tissue. The slight discrepancy in the magnitude of transcript vs. 
protein expression may indicate the presence of other factors affecting the ultimate 
translation of the gene. When comparing TFF1 expression to ERα expression, one would 
expect a direct relationship between the two proteins. In our study, such a relationship 
does not exist. TFF1 mRNA expression did not increase in primary tumor specimens 
which had a notable increase in ERα mRNA expression. Our data is converse to 
previously established data that shows a direct relationship between ERα expression and 
TFF1 (192). This may suggest the existence of estrogen-independent pathways or of 
interfering pathways affecting TFF1 expression. The interfering agent may, in fact, be 
MTA1, the suppressor of genes under the control of EREs. These data suggest MTA1 
functionality in SIC as the expression of TFF1, a gene under the control of ERE, is 
decreased in the presence of MTA1 upregulation. 
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10d. HDAC2 Functionality in SIC 
While demonstrating the presence of HDAC2 in SIC, the functionality of the 
enzyme is of even greater importance. The results of the HDAC activity assay with 
colorimetric histone deacetylate lysyl substrate indicate a significant increase in enzyme 
activity in SICs as compared to normal mucosa. The addition of Trichostatin A greatly 
reduced HDAC activity in both normal and tumor specimens. As in other cancers (146, 
148), HDAC inhibitors may be a therapeutic intervention in SIC treatment. 
The AQUA analysis of the acetylation status of Histone 2B (H2B) provides 
further evidence of HDAC2 functionality in SIC. Acetylated H2B was significantly 
decreased in SIC and their metastases as compared to normal mucosa. An examination of 
the acetylated to non-acetylated H2B ratios in normal and carcinoid tissues further 
suggests a role for histone deacetylation in SIC tumor progression. 
10e. ERα and HER2 in SIC 
In previous studies, the existence of ERα in carcinoid tumors was a point of 
contention. Chan et al. demonstrated hypermethylation of the ERα promoter region in 
neuroendocrine tumors (185). In our study, we have demonstrated both ERα message and 
protein expression in SICs. While levels of protein staining amongst normal, primary, 
and liver metastatic SIC tissue did not vary significantly, the general pattern in both the 
Q-RT-PCR and AQUA analyses revealed downward trend in expression levels. This is 
similar to the ERα message expression pattern in breast cancer, where the presence of 
estrogen receptors typically indicates slower-growing tumors that may be amenable to 
hormonal manipulation (180). Focusing on the nuclear ERα protein expression, the lack 
of significant variation in protein expression in normal and tumor specimens may indicate 
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a lack of ERα importance as a prognostic indicator in SIC patients. This also diminishes 
support for the use of ERα-targeting therapies such as Tamoxifen in the treatment of this 
tumor type. In addition, MTA1 and the estrogen receptor were previously shown to have 
an inverse relationship in the study of hepatocellular carcinoma, suggesting a possible 
regulatory role for MTA1 (12). This relationship was not found in our study of the SICs. 
This may perhaps be due to the lack of variance in ERα expression and thus, 
underscoring the notion that ERα may be of little or no significance in SIC tumorigenesis. 
Amplification of HER2/neu, a protooncogene related to the epidermal growth 
factor receptor (193), has prognostic significance in patients with breast cancer.(178) 
HER2/neu protein expression using conventional staining dilutions (1:10,000) has not 
been identified in GI carcinoids (194). At higher antibody concentrations, HER2 has been 
identified in 31% of carcinoid tumors (195). In our investigation of SIC tumors, HER2 
mRNA expression was low compared to normal. There was a small decrease in 
expression levels when comparing primary to metastatic tumor and a similar pattern was 
seen in the AQUA analysis of HER2. This receptor is present, but not overexpressed in 
SICs. Of note is the fact that is was necessary to use a higher level of antibody 
concentration than the amount normally utilized in the TMA analysis of breast tissue. 
This requisite for our study suggests that HER2 may not be of biological significance in 
SIC. Combining this notion with our current understanding of Herceptin as a HER2-
targeted therapy, it becomes apparent that this, too, may not be a viable option for small 
intestinal carcinoid therapy. In addition, many breast studies, in both clinical and basic 
science settings, have drawn an inverse relationship between HER2 and ERα (196-198). 
In our study, the existence of such a relationship was impossible to determine given the 
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lack of variation in expression levels of these proteins between normal and tumor 
samples. 
Since HER2 and ERα gene and protein expression appears to be of little 
importance in SIC, we propose that MTA1, while a potential marker of SIC malignancy, 
is not under the control of HER2, as seen in the breast model (8). It may, however, be 
functional in SIC as it may induce the repression of TFF1, suggested by the inverse 
relationship between the two. 
10f. Exploration of the Hergulin/HER2 pathway as a Means of MTA1 Expressional 
Control in SICs 
In addition to exploring the potential presence of epigenetic factors in SIC 
tumorigenesis, we sought to define pathways of upregulation of the MTA1 complex. In 
defining these pathways, it was of paramount importance to delineate the inducers of 
MTA1 expression, hence the induction of malignant progression. 
As proposed by Mazumdar et al. (8), heregulin, by binding to the HER2/neu 
receptor, can induce MTA1 expression. The Q-RT-PCR and AQUA studies confirmed 
the presence of MTA1 in normal, primary tumor, and metastatic tissues, indicating a 
concomitant increase in gene and protein expression levels as the neoplastic process 
evolved. We, however, failed to detect a role for HER2 in carcinoid development. 
Message levels decreased in the progression from normal to tumor and metastatic tissue. 
Alterations in protein expression, however, failed to support a role for HER2 in SIC 
development. The MTA1 and HER2 data were incongruent, indicating the presence of 
other means of transcriptional activation of MTA1 in SIC. 
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10g. Exploration of Other Mechanisms of MTA1 Expression Control 
The negative HER2 findings led to the exploration of the promoter region of the 
MTA1 gene. Through use of the Ensembl® v36 genome database and MTA1 promoter 
region analysis, we identified nucleotide patterns associated with transcription factor 
response elements including SP1 (GGGCGG), c-myc/Max (CACGTG), c-Fos/c-Jun 
(TGACTCA & TGAGTAA). In addition, we observed 2 CpG Island rich areas proximal 
to the start codon (ATG).  
10h. CpG Island Methylation as a Means of Control of MTA1 Expression in SIC 
CpG Islands are typically sites of DNA methylation- a means of epigenetic 
control of gene expression. The aberrant demethylation of the MTA1 promoter region 
may be the cause of this gene’s upregulation in SIC and their metastases. Despite 
attempts to adjust annealing temperatures and MgCl2 concentrations, we were 
unsuccessful in our efforts to amplify the promoter region. It is possible that the samples 
(gy1-4) were degraded, but this is unlikely due to the fact that other genes were isolated 
from these samples (DATA NOT SHOWN).  
After the isolation of the promoter region, future investigations would have 
involved methylation-specific PCR of primary SIC, their metastases, and normal small 
intestinal tissue. The establishment of methylation patterns in the MTA1 promoter region 
could unveil the presence of aberrant demethylation, resulting in MTA1 overexpression. 
To further explore the potential role of aberrant demethylation in MTA1 upregulation, 
efforts should also be directed towards the analysis of demethylating enzymes such as 
DNA demethylase (199). Aberrant demethylation has been found in ovarian cancer to 
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induce HER2 and survivin expression (200). Similar demethylating events may occur in 
SICs. 
Efforts are currently being redirected towards the development of a GI carcinoid 
cell line with which functional in vitro studies on cell growth and motility may be 
performed. In addition, cell transformation and deletional analyses will be possible. 
 
11. CONCLUSION 
The impetus behind this project was the requirement to include molecular 
analyses in carcinoid tumor classification. Today’s tumor classification practices 
incorporate gross pathological, histological, clinical, and biochemical criteria. While 
helpful, the current system fails to provide a means of accurate diagnosis, 
prognostication, and assessment of optimal treatment plan. Molecular analysis should 
facilitate the improved classification of carcinoids, as well as provide a means to 
delineate the molecular pathways involved in the tumorigenesis of SIC. 
The data from this investigation have demonstrated the presence and functionality 
of both HDAC2 and MTA1 in small intestinal carcinoids. These results support the 
potential role of aberrant epigenetic modulation in the development and evolution of SICs. 
The overexpression of HDAC2 and MTA1 has been identified in small intestinal 
carcinoids and suggest novel markers for carcinoid malignancy. Identification of HDAC2 
functionality in SIC suggests the potential therapeutic use of HDAC inhibitors in SIC 
patients. 
This study has also provided genetic and proteomic evidence of the lack of 
involvement of ERα and HER2 in SIC, a previous topic of debate. Low message and 
 59
protein levels of both ERα and HER2 indicate the lack of a role for these receptors in 
small intestinal carcinoid. In addition, such results underscore the reduced potential for 
HER2- or ERα- targeted therapy to eradicate carcinoid tumors. The discovery of the 
absence of a relationship between HER2 and MTA1 in our small intestinal carcinoid 
series (unlike the direct relationship in the breast model) indicates that other modes of 
MTA1 expressional control may require to be elucidated. The schematic below provides 




Future efforts should be directed specifically towards the relationship between c-
Myc and MTA1 and HDAC2 expression in SICs. C-Myc has already been implicated in 
the overexpression of MTA1 and HDAC2 in various cancers(6, 170). Studies have 
 
MTA1















Fig. 13. Schematic representing possible MTA1 pathway in SICs. Other regulators may include promoter 
methylation and c-MYC. 
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already shown the impact of c-Myc inhibition in cell cycle progression(201, 202). The 
elucidation of c-Myc’s role in SICs in association with MTA1 and HDAC2 will provide 
further delineation of SIC pathogenesis as well as the development of new therapeutic 
approaches.  
In sum, molecular analysis of SICs has great potential in changing the diagnostic 
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